Rare Medical News

Advertisement

Spotlight On

Alopecia totalis (AT)

Alopecia totalis is the loss of all skull and facial hair

Prevalence

30 / 100,000

99,300

US Estimated

154,050

Europe Estimated

Age of Onset

ICD-10

#N/A

Inheritance

This condition does not appear to have a clear pattern of inheritance.

Rare View

Alopecia areata (AA) is a chronic, autoimmune disorder of non-scarring hair loss mediated by T-lymphocytes against the hair follicular unit. Alopecia totalis (AT) is a condition characterized by the complete loss of hair on the scalp. It is an advanced form of alopecia areata a condition that causes round patches of hair loss.

5 Facts you should know

FACT

1

A condition characterized by the complete loss of hair on the scalp

FACT

2

An advanced form of alopecia areata

FACT

3

It is thought to be an autoimmune condition in which the immune system mistakenly attacks the hair follicles

FACT

4

Roughly 20% of affected people have a family member with alopecia

FACT

5

Among those in whom all body hair is lost, fewer than 10% recover

Alopecia totalis (AT) is also known as...

Alopecia totalis (AT) is also known as:

  • Loss of all scalp hair

What’s your Rare IQ?

In what form of hair loss is the entire body affected?

Common signs & symptoms

Alopecia of scalp

Pathologic hair loss from scalp
 

Current treatments

There is no cure, and available treatments are not usually effective for severe alopecia totalis.

Top Clinical Trials

TitleDescriptionPhasesStatusInterventionsMore Information
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATAThis is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).

Phase 2Active, not recruitingDrug: PF-06651600|Drug: PlaceboMore Info
Long-Term PF-06651600 for the Treatment of Alopecia AreataThis is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata.Phase 3Active, not recruitingDrug: PF-06651600|Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine|Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccineMore Info

Top Treatments in Research

AgentClass/Mechanism of ActionDevelopment StatusCompanyClinical StudiesMore Information
PF-06651600An irreversible inhibitor of JAK3 with selectivity over the other three JAK isoforms.Phase 2PfizerMore InfoMore Info